Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
biotech
boston blog main
boston top stories
cancer
6
×
investing
6
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
deals
pfizer
president trump
roche
startups
alexion pharmaceuticals
bristol-myers squibb
eli lilly
fda
What
drug
6
×
roundup
bio
alzheimer’s
annual
attention
biotech
cancer
companies
plan
prices
research
advantages
ahead
ambien
american
approved
asco
assessed
attendees
bar
brings
camp’s
cash
chicago
city
clinical
combinations
communities
community’s
conference
days
despite
different
digital
disease
epidemic
esmo
europe
expanding
Language
unset
Current search:
cancer
×
drug
×
photo
×
investing
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More